$7.13
0.99% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
NL0015285941
Symbol
IMTX
Sector
Industry

Immatics N.V Stock price

$7.13
-0.78 9.86% 1M
-4.66 39.53% 6M
-3.40 32.29% YTD
-3.76 34.53% 1Y
-5.65 44.21% 3Y
-7.92 52.62% 5Y
-7.92 52.62% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.07 0.99%
ISIN
NL0015285941
Symbol
IMTX
Sector
Industry

Key metrics

Market capitalization $851.01m
Enterprise Value $337.93m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.69
P/S ratio (TTM) P/S ratio 6.77
P/B ratio (TTM) P/B ratio 1.72
Revenue (TTM) Revenue $125.71m
EBIT (operating result TTM) EBIT $-72.52m
Free Cash Flow (TTM) Free Cash Flow $-49.33m
Cash position $547.44m
EPS (TTM) EPS $-0.65
P/E forward negative
P/S forward 7.06
EV/Sales forward 2.80
Short interest 6.84%
Show more

Is Immatics N.V a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Immatics N.V Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Immatics N.V forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Immatics N.V forecast:

Buy
100%

Financial data from Immatics N.V

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
126 126
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
-
18%
- Research and Development Expense 151 151
-
120%
-61 -61
-
-48%
- Depreciation and Amortization 12 12
-
9%
EBIT (Operating Income) EBIT -73 -73
636% 636%
-58%
Net Profit -60 -60
-
-48%

In millions USD.

Don't miss a Thing! We will send you all news about Immatics N.V directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immatics N.V Stock News

Neutral
GlobeNewsWire
about one month ago
The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics
Neutral
GlobeNewsWire
about 2 months ago
Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics' TCR-T PRAME franchise to target solid cancers
Positive
Seeking Alpha
3 months ago
Immatics is an early-stage biotech focused on cell-based immunotherapies for solid cancers. Their ACTEngine pipeline shows promise, particularly IMA203/IMA203CD8 targeting the PRAME antigen. Valuation estimates suggest a potential stock price of ~$19.26 based on conservative revenue assumptions.
More Immatics N.V News

Company Profile

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.

Head office Netherlands
CEO Harpreet Singh-Jasuja
Employees 343
Founded 2020
Website www.immatics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today